Immune checkpoint molecules have become significant diagnostic and therapeutic targets in laryngeal cancer, with PD-L1 (Programmed Death-Ligand 1) and CTLA-4 (Cytotoxic T-Lymphocyte Associated Protein 4) being the most prominent examples. This evidence concerns the gene CTLA4 and laryngeal carcinoma.